Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 2 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Lasix — FUROSEMIDE
Application NDA018579 (NDA)
Lasix — FUROSEMIDE
Application NDA018413 (NDA)
Lasix — FUROSEMIDE
Application NDA018790 (NDA)
Lasix — FUROSEMIDE
Application NDA018823 (NDA)
Lasix — FUROSEMIDE
Application NDA018868 (NDA)
Bumex — BUMEX
Application NDA018225 (NDA)
Bumex — BUMEX
Application NDA018226 (NDA)
Lasix — FUROSEMIDE
Application NDA018419 (NDA)
Trental — TRENTAL
Application NDA018631 (NDA)
Lasix — FUROSEMIDE
Application NDA019036 (NDA)
Lasix — FUROSEMIDE
Application NDA018750 (NDA)
Lasix — FUROSEMIDE
Application NDA018370 (NDA)
Lasix — FUROSEMIDE
Application NDA018902 (NDA)
Lasix — FUROSEMIDE
Application NDA018753 (NDA)
Lotensin — LOTENSIN
Application NDA019851 (NDA)
Anzemet — ANZEMET
Application NDA020624 (NDA)
Anzemet — ANZEMET
Application NDA020623 (NDA)
Lasix — FUROSCIX
Application NDA209988 (NDA)
Lasix — LASIX ONYU
Application NDA217294 (NDA)
Bumex — ENBUMYST
Application NDA219500 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)